Lilly revenue surges 56% to $19.8B on Mounjaro/Zepbound; new Medicare pricing deal announced

Filed April 30, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 1, 2025 · ~2 min read

Key Changes

• high

  Revenue grew 56% to $19.8B in Q1 2026, accelerating from 45% prior year, with Mounjaro and Zepbound now representing 65% of total revenue. Net income surged 168% to $7.4B (EPS $8.26) driven by higher gross margin and lower acquisition charges.

  MD&A: Financial Results verify on EDGAR →
• high

  Lilly finalized voluntary U.S. pricing agreements including lower Medicaid prices and a Medicare Bridge Program providing discounted obesity medicines to beneficiaries through end-2027. Company notes uptake is unknown and outcome could negatively impact pricing strategies across global markets.

  MD&A: Pricing Agreements verify on EDGAR →
• high

  FDA approved Foundayo (orforglipron), Lilly's oral GLP-1 for obesity, in April 2026. Phase 3 trials also met primary endpoints for orforglipron in type 2 diabetes and retatrutide in type 2 diabetes, strengthening late-stage pipeline.

  MD&A: Pipeline Updates verify on EDGAR →